The global T-cell acute lymphoblastic leukemia market is driven by rise in prevalence of T-cell acute lymphoblastic leukemia. The global market is projected to grow at a rapid pace during the forecast period. This is attributed to increase in cancer awareness programs and strong product pipeline.
T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia, with features similar to lymphoma. It affects white blood cells called T lymphocytes. T-ALL is most common among children aged over 5 years. Treatment of this disease includes chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. Rise in prevalence of T-ALL and rapid technological advancements boost the global T-cell acute lymphoblastic leukemia market. According to the American Society of Clinical Oncology (ASCO), T-cell acute lymphoblastic leukemia accounted for 15% to 20% of all acute lymphoblastic leukemia. According to a recent study, in 2017, nearly 5,970 cases of acute lymphoblastic leukemia (ALL) were reported in the U.S. About 4 in 10 cases were in adults. Moreover, increase in health care expenditure and rise in number of clinical trials are expected to fuel the global T-cell acute lymphoblastic leukemia market.
The global T-cell acute lymphoblastic leukemia market has been segmented based on treatment, end-user, and region. In terms of treatment, the global market has been classified into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The chemotherapy treatment segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at a significant CAGR during the forecast period due to its high prescription rate, wide range of products, and easy availability.
Based on end-user, the global T-cell acute lymphoblastic leukemia market has been categorized into hospitals, clinics, and others. The hospitals segment dominated the global market in 2017, and the trend is likely to continue during the forecast period. This is attributed to the increase in health care infrastructure, favorable reimbursement policies, and surge in awareness among individuals about T-ALL. Moreover, hospitals provide advanced medical treatment to treat T-cell acute lymphoblastic leukemia patients.
In terms of region, the global T-cell acute lymphoblastic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to gain market share by the end of 2026. The market in North America is driven by increase in incidence of T-cell acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure. The T-cell acute lymphoblastic leukemia market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Japan dominated the T-cell acute lymphoblastic leukemia market in the region. The market in India is expected to expand at a high CAGR during the forecast period.
Major players operating in the global T-cell acute lymphoblastic leukemia market include Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma, Inc., and Celgene Corporation. These companies have adopted the strategy of acquisition and collaboration in order to strengthen their positions in the global market.
Increasing Cases of Cancer and Leukemia to Attract Higher Revenues for T-cell Acute Lymphoblastic Leukemia Market
The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia is likely to emerge as the key driver of the global T-cell acute lymphoblastic leukemia market. White blood cell acute lymphoblastic leukemia (T-ALL) is a kind of acute lymphoblastic leukemia, with highlights like lymphoma. It influences white platelets called T lymphocytes. T-ALL is generally basic among kids matured more than 5 years. Therapy of this illness incorporates chemotherapy, radiation treatment, bone marrow relocate, directed treatment, and immunotherapy. Ascend in pervasiveness of T-ALL and fast innovative progressions help the worldwide T-cell acute lymphoblastic leukemia market. Also, expansion in medical services use and ascend in number of clinical preliminaries are required to fuel the worldwide T-cell acute lymphoblastic leukemia market.
Advancement in the drug area, government drives, rising medical care consumption, flood in innovative work, and flooding number of in persistent pool are assessed to spread out the worldwide market. Request regarding therapeutics for T-cell acute lymphoblastic leukemia has developed significantly in the recent years. This brought about expansion in clinical preliminaries in ahead of schedule and late phases of prescription turn of events.
Regionwise, North America held the largest share in the past and is likely to continue so in the coming years. This is attributed to the rising rate of T-cell acute lymphoblastic leukemia, new item endorsements, solid item pipeline, and ascend in medical care consumption. The T-cell acute lymphoblastic leukemia market in Asia Pacific is expected to develop at a quick speed during the estimate time frame. Japan ruled the T-cell acute lymphoblastic leukemia market around there.
Flooding progression in innovation and R&D exercises identified with assembling methods are projected to drill the profitability of drug advancement. In any case, staggering cost related with the treatment of T-cell acute lymphoblastic leukemia is expected to control the market in the approaching years. Advancement of therapeutics requires the usage of expensive instrumentation that also grows the overall expense of therapeutics and treatment for the illness.
The global T-cell acute lymphoblastic leukemia market has been segmented as below:
by Treatment |
|
by End-user |
|
by Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global T-cell Acute Lymphoblastic Leukemia Market
4. Market Overview
4.1. Introduction
4.2. Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
4.3. Global T-cell Acute Lymphoblastic Leukemia Market Outlook
4.4. Key Industry Developments
4.5. T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
4.6. Nelarabine: Clinical Trial
4.7. Acute Lymphocytic Leukemia New Cases, 2017
4.8. Reimbursement Scenario for Cancer Treatment
4.9. Regulatory Guidelines for Therapeutics
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
6. Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment
6.1. Introduction
6.2. Global T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
6.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
6.3.1. Chemotherapy
6.3.2. Radiation Therapy
6.3.3. Bone Marrow Transplant
6.3.4. Targeted Therapy
6.3.4. Immunotherapy
7. Global T-cell Acute Lymphoblastic Leukemia Market, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
7.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by End-user
7.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by End-user
7.5.1. Hospitals
7.5.2. Clinics
7.5.3. Others
7.6. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
8. T-cell Acute Lymphoblastic Leukemia Market Analysis, by Region
8.1. Key Findings
8.2. Global Market Scenario
8.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
8.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by Region
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East & Africa
8.5. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region
9. North America T-cell Acute Lymphoblastic Leukemia Market
9.1. Key Findings
9.2. North America T-cell Acute Lymphoblastic Leukemia Market Overview
9.3. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
9.4. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
9.6. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
9.6.1. Chemotherapy
9.6.2. Radiation Therapy
9.6.3. Bone Marrow Transplant
9.6.4. Targeted Therapy
9.6.4. Immunotherapy
9.7. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
9.8. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
9.8.1. Hospitals
9.8.2. Clinics
9.8.3. Others
9.9. North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
10. Europe T-cell Acute Lymphoblastic Leukemia Market
10.1. Key Findings
10.2. Europe T-cell Acute Lymphoblastic Leukemia Market Overview
10.3. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
10.4. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
10.6. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
10.6.1. Chemotherapy
10.6.2. Radiation Therapy
10.6.3. Bone Marrow Transplant
10.6.4. Targeted Therapy
10.6.4. Immunotherapy
10.7. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
10.8. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
10.8.1. Hospitals
10.8.2. Clinics
10.8.3. Others
10.9. Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
11. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market
11.1. Key Findings
11.2. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Overview
11.3. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
11.4. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of APAC
11.5. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
11.6. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
11.6.1. Chemotherapy
11.6.2. Radiation Therapy
11.6.3. Bone Marrow Transplant
11.6.4. Targeted Therapy
11.6.4. Immunotherapy
11.7. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
11.8. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
11.8.1. Hospitals
11.8.2. Clinics
11.8.3. Others
11.9. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
12. Latin America T-cell Acute Lymphoblastic Leukemia Market
12.1. Key Findings
12.2. Latin America T-cell Acute Lymphoblastic Leukemia Market Overview
12.3. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
12.4. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
12.6. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
12.6.1. Chemotherapy
12.6.2. Radiation Therapy
12.6.3. Bone Marrow Transplant
12.6.4. Targeted Therapy
12.6.4. Immunotherapy
12.7. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
12.8. Latin America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
12.8.1. Hospitals
12.8.2. Clinics
12.8.3. Others
12.9. Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
13. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market
13.1. Key Findings
13.2. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Overview
13.3. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
13.4. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
13.6. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
13.6.1. Chemotherapy
13.6.2. Radiation Therapy
13.6.3. Bone Marrow Transplant
13.6.4. Targeted Therapy
13.6.4. Immunotherapy
13.7. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
13.8. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
13.8.1. Hospitals
13.8.2. Clinics
13.8.3. Others
13.9. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2017)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Erytech Pharma Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Celgene Corporation
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
List of Tables
Table 01: T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
Table 02: Nelarabine: Clinical Trial
Table 03: Authorities Responsible for Reimbursement of Medicines in European Region, 2017
Table 04: Major Regulatory Agencies Responsible for Granting Marketing Authorization for Drugs
Table 05: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 06: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 07: Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 08: North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 10: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 11: Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 13: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 14: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 16: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 17: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 19: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 20: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 22: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 23: Products Offered (Pfizer, Inc.)
Table 24: Products Offered (Novartis AG)
Table 25: Products Offered (F. Hoffmann-La Roche Ltd.)
Table 26: Products Offered (Sanofi)
Table 27: Products Offered (Erytech Pharma, Inc.)
Table 28: Products Offered (Celgene Corporation)
List of Figures
Figure 01: Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2017
Figure 03: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by End-user, 2017
Figure 04: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Region, 2017
Figure 05: Regulatory Approval Process - U.S.
Figure 06: Regulatory Approval Process - Europe
Figure 07: Regulatory Approval Process - Japan
Figure 08: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 09: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 10: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy, 2016–2026
Figure 11: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
Figure 12: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant, 2016–2026
Figure 13: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
Figure 14: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
Figure 15: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 16: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals
Figure 17: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
Figure 18: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 19: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 20: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
Figure 21: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018–2026
Figure 22: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 23: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
Figure 24: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
Figure 25: North America T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 26: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 27: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 28: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 29: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 30: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 31: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 32: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 33: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 34: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 35: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 36: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 37: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 38: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 39: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 40: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 41: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 42: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 43: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 44: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 45: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 46: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 47: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 48: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 49: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 50: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 51: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 52: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 53: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 54: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 55: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 56: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 57: Global T-cell Acute Lymphoblastic Leukemia Market Share, by Company, 2017
Figure 58: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 59: Pfizer, Inc. Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 60: Pfizer, Inc. Revenue Share (%), by Business Segment, 2017
Figure 61: Pfizer, Inc. Revenue Share (%), by Region, 2017
Figure 62: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 63: Novartis AG Oncology Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 64: Novartis AG Net Sales (%), by Business Segment, 2017
Figure 65: Novartis AG Net Sales (%), by Region, 2017
Figure 66: F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
Figure 67: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
Figure 68: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue (%), by Specialty (2017)
Figure 69: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue (%), by Region (2017)
Figure 70: Sanofi Revenue (US$ Bn), 2014-2017
Figure 71: Sanofi Regional Sales Breakdown (%), 2017
Figure 72: Celgene Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 73: Celgene Corporation Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 74: Celgene Corporation Breakdown of Net Sales (%), by Business Segment, 2017
Figure 75: Celgene Corporation Breakdown of Net Sales (%), by Region, 2017